Schildkraut Joellen M, Abbott Sarah E, Alberg Anthony J, Bandera Elisa V, Barnholtz-Sloan Jill S, Bondy Melissa L, Cote Michele L, Funkhouser Ellen, Peres Lauren C, Peters Edward S, Schwartz Ann G, Terry Paul, Crankshaw Sydnee, Camacho Fabian, Wang Frances, Moorman Patricia G
Department of Public Health Sciences, University of Virginia, Charlottesville, Virginia.
Hollings Cancer Center and Department of Public Health Sciences, Medical University of South Carolina, Charleston, South Carolina.
Cancer Epidemiol Biomarkers Prev. 2016 Oct;25(10):1411-1417. doi: 10.1158/1055-9965.EPI-15-1281. Epub 2016 May 12.
Epidemiologic studies indicate increased ovarian cancer risk among women who use genital powder, but this has not been thoroughly investigated in African American (AA) women, a group with a high prevalence of use. We evaluate the relationship between use of genital powder and nongenital powder in invasive epithelial ovarian cancer (EOC).
Subjects are 584 cases and 745 controls enrolled in the African American Cancer Epidemiology Study (AACES), an ongoing, population-based case-control study of EOC in AA women in 11 geographic locations in the United States. AA controls were frequency matched to cases on residence and age. Logistic regression was used to calculate ORs and 95% confidence intervals (CI) for associations between genital and nongenital powder exposure and EOC risk, controlling for potential confounders.
Powder use was common (62.8% of cases and 52.9% of controls). Genital powder was associated with an increased risk of EOC (OR = 1.44; 95% CI, 1.11-1.86) and a dose-response relationship was found for duration of use and number of lifetime applications (P < 0.05). Nongenital use was also associated with EOC risk, particularly among nonserous EOC cases (OR = 2.28; 95% CI, 1.39-3.74). An association between powder use and upper respiratory conditions suggests an enhanced inflammatory response may explain the association between body powder and EOC.
In a study of AA women, body powder use was significantly associated with EOC risk.
The results support that body powder is a modifiable risk factor for EOC among AA women. Cancer Epidemiol Biomarkers Prev; 25(10); 1411-7. ©2016 AACRSee related commentary by Trabert, p. 1369.
流行病学研究表明,使用外阴部粉剂的女性患卵巢癌的风险增加,但在使用该粉剂的比例较高的非裔美国女性中,尚未对此进行充分研究。我们评估了侵袭性上皮性卵巢癌(EOC)中外阴部粉剂和非阴部粉剂的使用与发病风险之间的关系。
研究对象为584例病例和745例对照,来自非裔美国癌症流行病学研究(AACES),这是一项正在进行的、基于人群的病例对照研究,涉及美国11个地理位置的非裔美国女性EOC患者。非裔美国对照在居住地和年龄上与病例进行频率匹配。采用逻辑回归计算外阴部和非阴部粉剂暴露与EOC风险之间关联的比值比(OR)和95%置信区间(CI),并对潜在混杂因素进行控制。
粉剂使用很常见(62.8%的病例和52.9%的对照)。外阴部粉剂与EOC风险增加相关(OR = 1.44;95% CI,1.11 - 1.86),且发现使用持续时间和终生使用次数存在剂量反应关系(P < 0.05)。非阴部使用也与EOC风险相关,尤其是在非浆液性EOC病例中(OR = 2.28;95% CI,1.39 - 3.74)。粉剂使用与上呼吸道疾病之间的关联表明,增强的炎症反应可能解释了身体用粉剂与EOC之间的关联。
在一项针对非裔美国女性的研究中,身体用粉剂的使用与EOC风险显著相关。
结果支持身体用粉剂是导致非裔美国女性患EOC的一个可改变的风险因素。《癌症流行病学、生物标志物与预防》;25(10);1411 - 7。©2016 AACR见Trabert的相关评论,第1369页。